PBS Biotech buys Integrity to add manufacturing capacity
Under PBS’ ownership, Camarillo, California-based Integrity will focus on the production and testing of disposable bio-production reaction vessels, culture bags and associated plastic components.
PBS spokesman James Schultz told Outsourcing-pharma.com the acquisition, financial terms of which were not disclosed, was motivated by the company’s need for additional cleanroom capacity to keep up with growing pharmaceutical industry demand.
“We had planned to purchase over 4,000 sq ft of clean room facility. That can easily be accommodated with the clean room operations we acquired with Integrity and existing facilities.
He also said that, while the manufacture of bioprocess vessels will be Integrity’s main focus under PBS' ownership, the company will continue to operate its medical device contract development and manufacturing business.
“PBS will fold Integrity into ongoing operations. That means the manufacturing arm of the company will continue to support both existing and new customers.
Schultz also confirmed that PBS plans to hire additional staff, with the aim of doubling its workforce in the next 12 to 18 months.
The Integrity acquisition follows just a few months after PBS expanded its range of bioreactors with new single use manufacturing system, the PBS 3, for the production of vaccines, biotherapeutics and biosimilars.
News of the deal marks the end of a good month for PBS which, on August 18, was named as ‘Business of the Year’ by the Pacific Coast Business Times.
The US newspaper said the award was in recognition of “excellence in business and for positive contributions to the local, US and international economy and community."
